RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their commercialization. Major players saw messenger RNA (mRNA) vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine for COVID-19, followed by others such as Pfizer and BioNTech. mRNA is the first form of RNA vaccine to complete clinical trials and commercialization. Frost & Sullivan’s analysis shows participants are developing mRNA vaccines for influenza, HIV, and cancer.
• RNA design and optimization are essential to obtain RNA forms that suit vaccine development and provide the expected outcomes.
• Self-amplifying mRNA (saRNA) vaccines are considered the next-generation RNA vaccines with improved properties and more advantages over mRNA vaccines.
• Meanwhile, circular RNA vaccines are emerging due to enhanced properties such as stability and higher protein expressions.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
